e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Treatment of human pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Switch from sitaxentan to another ERA in PAH: Single center short term safety observations
T. Lange, M. Arzt, M. Pfeifer (Regensburg, Donaustauf, Germany)
Source:
Annual Congress 2011 - Treatment of human pulmonary hypertension
Session:
Treatment of human pulmonary hypertension
Session type:
Thematic Poster Session
Number:
2283
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Lange, M. Arzt, M. Pfeifer (Regensburg, Donaustauf, Germany). Switch from sitaxentan to another ERA in PAH: Single center short term safety observations. Eur Respir J 2011; 38: Suppl. 55, 2283
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE
Source: Virtual Congress 2021 – Therapy of pulmonary hypertension
Year: 2021
Functional effects of long term ICS treatment in controlled asthma
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Long term outcome of PAH therapy - the past and the future
Source: Annual Congress 2008 - Current and future pulmonary arterial hypertension combination therapy
Year: 2008
Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study
Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis
Year: 2020
Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019
Efficacy of CPAP and NIV in long term treatment of OHS: the results of the Spanish multicentre randomised trial "Pickwicks"
Source: International Congress 2015 – Sleep-disordered breathing
Year: 2015
Late Breaking Abstract - Long-term safety of pirfenidone in a real-world setting: final results from the prospective, observational PASSPORT registry
Source: International Congress 2017 – Late-breaking findings in pulmonary diseases
Year: 2017
Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial - Design and efficacy data
Source: Annual Congress 2008 - Clinical trial - Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial
Year: 2008
Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial - Safety data
Source: Annual Congress 2008 - Clinical trial - Understanding the potential long-term impacts on function with Tiotropium: the UPLIFT trial
Year: 2008
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Feasibility of digital long term follow up after pulmonary rehabilitation in patients with COPD: a pilot study
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020
Long-term safety data with once-daily budesonide in mild asthma: results from the START study
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003
Long term outcomes of immunomodulatory drugs in SSc-ILD - data from the German SSc-network
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Safety and tolerability to long term moxifloxacin treatment in 38 patients with difficult to manage tuberculosis: preliminary data
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004
Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept